Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

(2014) John B. Buse et al.   DIABETES CARE

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

(2014) C. Mathieu et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

(2014) Asger Lund et al.   European Journal of Internal Medicine

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

(2014) Stephen C L Gough et al.   Lancet Diabetes & Endocrinology

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review

(2013) Markolf Hanefeld et al.   Cardiovascular Diabetology

Combining Incretin-Based Therapies With Insulin: Realizing the potential in type 2 diabetes

(2013) J. Vora   DIABETES CARE

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Incretin hormones and the satiation signal

(2013) J J Holst   INTERNATIONAL JOURNAL OF OBESITY

Patterns and trends in insulin intensification among patients with type 2 diabetes: A systematic review

(2013) Jennifer M. Polinski et al.   Primary Care Diabetes

Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study

(2013) Bradley Curtis et al.   JOURNAL OF MEDICAL ECONOMICS

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin degludec: overview of a novel ultra long-acting basal insulin

(2012) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin

(2012) B. T. Blak et al.   DIABETIC MEDICINE

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

Type 2 Diabetes Care and Insulin Intensification

(2010) Robert M. Cuddihy et al.   DIABETES EDUCATOR

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Barriers to insulin initiation and intensification and how to overcome them

(2009) T. Kunt et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET